J Horton

Summary

Publications

  1. ncbi request reprint Global anthelmintic chemotherapy programs: learning from history
    John Horton
    Trends Parasitol 19:405-9. 2003
  2. pmc A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project
    Corinne S C Merle
    Faculty of Epidemiology and Population Health, Tropical Epidemiological Group, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Trials 13:61. 2012
  3. doi request reprint The development of albendazole for lymphatic filariasis
    J Horton
    Tropical Projects, 24 The Paddock, Hitchin SG4 9EF, UK
    Ann Trop Med Parasitol 103:S33-40. 2009
  4. ncbi request reprint Albendazole for the treatment of echinococcosis
    John Horton
    GlaxoSmithKline, GSK House, 980, Great West Road, Brentford, UK
    Fundam Clin Pharmacol 17:205-12. 2003
  5. ncbi request reprint Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations
    John Horton
    Deseases of the Developing World, GlaxoSmithKline, Brentford, UK
    Curr Opin Infect Dis 15:599-608. 2002
  6. ncbi request reprint Proposing the motion
    John Horton
    Tropical Projects, 24 The Paddock, Hitchin, Hertfordshire SG4 9EF, UK
    Trans R Soc Trop Med Hyg 97:12-3. 2003
  7. ncbi request reprint An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis
    J Horton
    Department of Therapeutics Tropical Medicine, SmithKline Beecham International, Brentford, Mliddlesex, UK
    Parasitology 121:S147-60. 2000
  8. ncbi request reprint Human gastrointestinal helminth infections: are they now neglected diseases?
    John Horton
    Department of Pharmacology and Therapeutics, University of Liverpool, Ashton Street, Liverpool L69 3GE, UK
    Trends Parasitol 19:527-31. 2003
  9. ncbi request reprint Progress over a decade, a century, a millennium
    John Horton
    Cancer Control 10:4. 2003
  10. ncbi request reprint A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya
    Monique K Wasunna
    Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
    Am J Trop Med Hyg 73:871-6. 2005

Collaborators

  • C N Wamae
  • R K Shenoy
  • M M Ismail
  • J O Gyapong
  • V Y Belizario
  • K Awadzi
  • J K Baird
  • Shyam Sundar
  • Annette Olsen
  • T Junghanss
  • Corinne S C Merle
  • Juventus B Ziem
  • J Mark Felton
  • Monique K Wasunna
  • Tara K Jha
  • Antony J Sabin
  • Tabe Ebob Tabi
  • Braden R Hale
  • Charalambos Sismanidis
  • Piero Olliaro
  • Martin Gninafon
  • Katherine Fielding
  • Denis A Mitchinson
  • Francoise Portaels
  • Roxana Rustomjee
  • Olivier Lapujade
  • Christian Lienhardt
  • Christian Perronne
  • Oumou Bah Sow
  • Mame Bocar Lo
  • Joseph Odhiambo
  • Von L L Asigri
  • Anton M Polderman
  • Pascal Magnussen
  • Dedan Kinoti
  • George Kirigi
  • Jane Mbui
  • Juma R Rashid
  • Chandreshwar P Thakur
  • M John Albert
  • Hudson Lodenyo
  • Alain Folefack
  • Rose Leke
  • Thomas B Nutman
  • Philomene Gwanmesia
  • Rosa Befidi-Mengue
  • Edith Pensia
  • Rellinds Fualem
  • Isabella Quakyi
  • Josephine Fogako
  • Stephen L Hoffman
  • W Roy Prescott
  • Thomas L Ritchie
  • Kwadwo A Koram
  • Francis Nkrumah
  • Eileen D Franke
  • Fred N Binka
  • Martin Adjuik
  • David J Fryauff
  • Seth Owusu-Agyei
  • Abraham R Oduro

Detail Information

Publications16

  1. ncbi request reprint Global anthelmintic chemotherapy programs: learning from history
    John Horton
    Trends Parasitol 19:405-9. 2003
    ..The challenge will now be to make it happen, and some of the problems ahead are truly massive...
  2. pmc A pivotal registration phase III, multicenter, randomized tuberculosis controlled trial: design issues and lessons learnt from the Gatifloxacin for TB (OFLOTUB) project
    Corinne S C Merle
    Faculty of Epidemiology and Population Health, Tropical Epidemiological Group, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK
    Trials 13:61. 2012
    ..re-infections in the definition of the outcome? What is the optimal length of patient follow-up? Is blinding appropriate when treatment duration in test arm is shorter? What are the appropriate assumptions for sample size calculation?..
  3. doi request reprint The development of albendazole for lymphatic filariasis
    J Horton
    Tropical Projects, 24 The Paddock, Hitchin SG4 9EF, UK
    Ann Trop Med Parasitol 103:S33-40. 2009
    ..While there is no doubt about the efficacy of albendazole for the treatment of many helminth diseases, as a single agent it could never be recommended for filariasis...
  4. ncbi request reprint Albendazole for the treatment of echinococcosis
    John Horton
    GlaxoSmithKline, GSK House, 980, Great West Road, Brentford, UK
    Fundam Clin Pharmacol 17:205-12. 2003
    ..As diagnostic tools are ever more widely available, the question as to who should be treated in endemic communities has to be answered...
  5. ncbi request reprint Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations
    John Horton
    Deseases of the Developing World, GlaxoSmithKline, Brentford, UK
    Curr Opin Infect Dis 15:599-608. 2002
    ..This review highlights some important steps in fundamental research and the management of helminth disease that have occurred in the past year, appearing in the published literature...
  6. ncbi request reprint Proposing the motion
    John Horton
    Tropical Projects, 24 The Paddock, Hitchin, Hertfordshire SG4 9EF, UK
    Trans R Soc Trop Med Hyg 97:12-3. 2003
  7. ncbi request reprint An analysis of the safety of the single dose, two drug regimens used in programmes to eliminate lymphatic filariasis
    J Horton
    Department of Therapeutics Tropical Medicine, SmithKline Beecham International, Brentford, Mliddlesex, UK
    Parasitology 121:S147-60. 2000
    ..Additional data are also recommended for populations infected with Brugia malayi, since most data thus far derive from populations infected with Wuchereria bancrofti...
  8. ncbi request reprint Human gastrointestinal helminth infections: are they now neglected diseases?
    John Horton
    Department of Pharmacology and Therapeutics, University of Liverpool, Ashton Street, Liverpool L69 3GE, UK
    Trends Parasitol 19:527-31. 2003
  9. ncbi request reprint Progress over a decade, a century, a millennium
    John Horton
    Cancer Control 10:4. 2003
  10. ncbi request reprint A phase II dose-increasing study of sitamaquine for the treatment of visceral leishmaniasis in Kenya
    Monique K Wasunna
    Center for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
    Am J Trop Med Hyg 73:871-6. 2005
    ..5 mg/kg/day and 3.0 mg/kg/day dose groups had a severe renal adverse event. The effects of sitamaquine on the kidney need further investigation. Sitamaquine was efficacious and generally well tolerated in Kenyan patients with VL...
  11. ncbi request reprint A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India
    Tara K Jha
    Kala azar Research Center, Muzaffarpur, India
    Am J Trop Med Hyg 73:1005-11. 2005
    ..Nephrotic syndrome (3% [3 of 120]) and glomerulonephritis (2% [2 of 120]) were also reported and require further investigation. Oral sitamaquine demonstrated efficacy in Indian VL and was well tolerated...
  12. ncbi request reprint Breast cancer in 2020: what can we expect?
    John Horton
    Cancer Detect Prev 30:109-10. 2006
  13. ncbi request reprint Impact of repeated mass treatment on human Oesophagostomum and hookworm infections in northern Ghana
    Juventus B Ziem
    Department of Parasitology, Leiden University Medical Centre, Leiden, The Netherlands
    Trop Med Int Health 11:1764-72. 2006
    ..The prospects of eliminating human oesophagostomiasis from the intervention area, while simultaneously achieving an important reduction of hookworm prevalences by albendazole mass treatment, are discussed...
  14. ncbi request reprint Clinical management of cystic echinococcosis: state of the art, problems, and perspectives
    Thomas Junghanss
    Section of Clinical Tropical Medicine, University Hospital Heidelberg, Heidelberg, Germany
    Am J Trop Med Hyg 79:301-11. 2008
    ..In this paper, we review the current management procedures of CE with particular emphasis on the evidence base and setting-specific problems...
  15. ncbi request reprint A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum
    Braden R Hale
    US Navy Medical Research Unit No 3, Cairo, Egypt
    Clin Infect Dis 36:541-9. 2003
    ..Tafenoquine dosages of 50, 100, and 200 mg/week were safe, well tolerated, and effective against P. falciparum infection in this study population...
  16. ncbi request reprint Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen
    Tabe Ebob Tabi
    Biotechnology Center, Yaounde, Cameroon
    Am J Trop Med Hyg 71:211-5. 2004
    ..Most subjects continued to have elevations in microfilaremia, suggesting that more intensive regimens of albendazole will be necessary to reduce Loa microfilaremia to levels safe enough to allow for ivermectin use...